-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Multiple Myeloma: A Paradigm for Blending Community and Academic Care

Program: Education Program
Session: How Can We Manage High-Risk Hematologic Malignancies in the Community?
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human
Monday, December 11, 2023, 4:30 PM-5:45 PM

Jesus G. Berdeja, MD

Sarah Cannon Research Institute, Nashville, TN

Disclosures: Berdeja: Cartesian: Research Funding; Celularity: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; EMD Serono: Research Funding; Fate Therapeutics: Research Funding; Genentech: Research Funding; GSK: Research Funding; Ichnos Sciences: Research Funding; Incyte: Research Funding; Janssen: Consultancy, Research Funding, Speakers Bureau; Karyopharm: Research Funding; Kite Pharma: Consultancy; Legend Biotech: Consultancy; Lilly: Research Funding; Novartis: Research Funding; Poseida: Research Funding; Sanofi: Research Funding; 2seventy bio: Consultancy, Research Funding; C4 Therapeutics: Research Funding; Amgen: Research Funding; Celgene: Consultancy, Research Funding; CARsgen: Research Funding; AbbVie: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Acetylon: Research Funding; Takeda: Consultancy, Research Funding; Roche: Consultancy; Teva: Research Funding.

See more of: How Can We Manage High-Risk Hematologic Malignancies in the Community?
See more of: Education Program
<< Previous Presentation | Next Presentation >>